Search research articles
Contact Us
Filters
Showing results (21-30 of 163) with videos related to
Page
of 17
Sort By:
Oncoimmunology
|
January 23, 2015
Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity
Philipp Müller, Kea Martin, Sebastian Theurich, et al.
Cancer Immunology, Immunotherapy : CII
|
December 6, 2019
A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression
Richard Klar, Sven Michel, Monika Schell, et al.
Journal for Immunotherapy of Cancer
|
April 23, 2015
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
Heinz Läubli, Cathrin Balmelli, Matthias Bossard, et al.
Swiss Medical Weekly
|
February 11, 2015
Cancer immunology - development of novel anti-cancer therapies
Sacha I Rothschild, Daniela S Thommen, Wolfgang Moersig, et al.
Science Translational Medicine
|
November 9, 2022
Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment
Nicole Kirchhammer, Marcel P Trefny, Priska Auf der Maur, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
December 22, 2006
Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin
Laura Strauss, Theresa L Whiteside, Ashley Knights, et al.
Cancer Immunology, Immunotherapy : CII
|
March 1, 2018
The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models
Heinz Läubli, Philipp Müller, Lucia D'Amico, et al.
Nature Reviews. Cancer
|
October 2, 2025
Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment
Alfred Zippelius, Sara M Tolaney, Paolo Tarantino, et al.
Journal of the National Cancer Institute
|
June 14, 2015
Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy
Gongda Xue, Alfred Zippelius, Andreas Wicki, et al.
Trends in Immunology
|
July 10, 2002
Melan-A/MART-1-specific CD8 T cells: from thymus to tumor
Mikaël J Pittet, Alfred Zippelius, Danila Valmori, et al.
Page
of 17
Search research articles
Search
Showing results (21-30 of 163) with videos related to
Sort By:
Page
of 17
Oncoimmunology
|
January 23, 2015
Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity
Philipp Müller, Kea Martin, Sebastian Theurich, et al.
Cancer Immunology, Immunotherapy : CII
|
December 6, 2019
A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression
Richard Klar, Sven Michel, Monika Schell, et al.
Journal for Immunotherapy of Cancer
|
April 23, 2015
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
Heinz Läubli, Cathrin Balmelli, Matthias Bossard, et al.
Swiss Medical Weekly
|
February 11, 2015
Cancer immunology - development of novel anti-cancer therapies
Sacha I Rothschild, Daniela S Thommen, Wolfgang Moersig, et al.
Science Translational Medicine
|
November 9, 2022
Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment
Nicole Kirchhammer, Marcel P Trefny, Priska Auf der Maur, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
December 22, 2006
Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin
Laura Strauss, Theresa L Whiteside, Ashley Knights, et al.
Cancer Immunology, Immunotherapy : CII
|
March 1, 2018
The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models
Heinz Läubli, Philipp Müller, Lucia D'Amico, et al.
Nature Reviews. Cancer
|
October 2, 2025
Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment
Alfred Zippelius, Sara M Tolaney, Paolo Tarantino, et al.
Journal of the National Cancer Institute
|
June 14, 2015
Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy
Gongda Xue, Alfred Zippelius, Andreas Wicki, et al.
Trends in Immunology
|
July 10, 2002
Melan-A/MART-1-specific CD8 T cells: from thymus to tumor
Mikaël J Pittet, Alfred Zippelius, Danila Valmori, et al.
Page
of 17